Imagine CRISPR — but more efficient, reliable and flexible. The SNIPER screening platform works in synergy with CRISPR-Cas9 to fulfil the most challenging gene editing projects. With our CRISPR-SNIPER service, you can save time and money by eliminating unfeasible modifications at an early stage.
With CRISPR-SNIPER, you can achieve genome modifications that are challenging using CRISPR alone, meaning it is easier to:
Where editing efficiency normally decreases when the size of your gene exceeds 2 kbp, CRISPR-SNIPER is able to insert gene fragments up to 7 kbp in size.
The CRISPR-SNIPER system makes it possible to insert reporter genes at a higher success rate than with CRISPR-Cas9 alone.
This includes fluorescence genes which can be used to track changes in gene expression throughout iPSC development or antibacterial resistance genes which can be used to track selection.
SNIPER gives you the power to simultaneously edit multiple genes with low passage number, therefore protecting your cells from the effects of extended passaging and increasing the reliability of your data. This includes the ability to knock-in or knock-out up to five genes in a single experiment.
SNIPER’s enhanced sensitivity allows the generation of homozygous and heterozygous disease models with enhanced accuracy. This expands the range of disease phenotypes you can explore with CRISPR, allowing you to reliably observe genotype to phenotype relationships.
Our gene editing services can be used to edit a range of cell types, including iPSCs. This makes CRISPR CRISPR-SNIPER the ideal technology for the generation of custom disease models for drug screening. You can read more about our custom iPSC-derived disease models here.
With SNIPER, our scientists can assess whether your desired modification is possible within two weeks — eliminating impossible experiments at an early stage.
With a 95% success rate, including even the most challenging modifications, our team can deliver results you can trust sooner than any other company — saving you time and money.